Giuseppe Lamberti, MD, University Hospital of Bologna, Bologna, Italy, shares insight on data collected on patients with KRASG12C non-small cell lung cancer (NSCLC) who received the KRASG12C inhibitors sotorasib or adegrasib as a single agent. Clinicopathologic and genomic features of the tumors were collected by either plasma or tumor next-generation sequencing wand were correlated with overall response rate (ORR), progression-free survival (PFS) and overall-survival (OS). Performance status and later treatments lines were found to be associated with worse prognosis. Additionally, STK11 co-mutations and CDKN2A deficiency were associated with worse PFS. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.